Benzimidazo[1,2-c]quinazolines: a new class of antitumor compounds.
A series of substituted benzimidazo[1,2-c]quinazolines have been synthesized. This class of compound has been designed by structural comparison with other intercalator patterns. The determination of in vitro activities has shown high inhibitory values.
Braña
M F
MF
Laboratorios Knoll S.A., Madrid, Spain.
Castellano
J M
JM
Keilhauer
G
G
Machuca
A
A
Martín
Y
Y
Redondo
C
C
Schlick
E
E
Walker
N
N
D000818:Animals; D000970:Antineoplastic Agents / Q000138:chemical synthesis* / Q000494:pharmacology / Q000627:therapeutic use; D001562:Benzimidazoles / Q000138:chemical synthesis* / Q000494:pharmacology / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000473:pathology; D002455:Cell Division / Q000187:drug effects; D003110:Colonic Neoplasms / Q000473:pathology; D018360:Crystallography, X-Ray; D004247:DNA / Q000096:biosynthesis; D006801:Humans; D007364:Intercalating Agents; D007939:Leukemia L1210 / Q000473:pathology; D008968:Molecular Conformation; D015394:Molecular Structure; D012516:Osteosarcoma / Q000473:pathology; D011799:Quinazolines / Q000138:chemical synthesis* / Q000494:pharmacology / Q000627:therapeutic use; D014407:Tumor Cells, Cultured
C092455:6-(2-(piperidino)ethylamino)benzimidazo(1,2-c)quinazoline; D000970:Antineoplastic Agents; D001562:Benzimidazoles; D007364:Intercalating Agents; D011799:Quinazolines; D004247:DNA